JP5926821B2 - 2−アリールベンゾフラン−7−カルボキサミド系化合物、その製造方法および用途 - Google Patents
2−アリールベンゾフラン−7−カルボキサミド系化合物、その製造方法および用途 Download PDFInfo
- Publication number
- JP5926821B2 JP5926821B2 JP2014555927A JP2014555927A JP5926821B2 JP 5926821 B2 JP5926821 B2 JP 5926821B2 JP 2014555927 A JP2014555927 A JP 2014555927A JP 2014555927 A JP2014555927 A JP 2014555927A JP 5926821 B2 JP5926821 B2 JP 5926821B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- methyl
- mmol
- esi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 82
- 150000001875 compounds Chemical class 0.000 title claims description 78
- -1 tetrahydrofuran-3-yl group Chemical group 0.000 claims description 27
- 229910052757 nitrogen Inorganic materials 0.000 claims description 22
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 229940041181 antineoplastic drug Drugs 0.000 claims description 4
- 229940125782 compound 2 Drugs 0.000 claims description 4
- 229940126214 compound 3 Drugs 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 125000005936 piperidyl group Chemical group 0.000 claims description 4
- 238000006798 ring closing metathesis reaction Methods 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 3
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 238000005915 ammonolysis reaction Methods 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 229940125898 compound 5 Drugs 0.000 claims description 2
- 230000002140 halogenating effect Effects 0.000 claims description 2
- 238000006192 iodination reaction Methods 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
- 229960004889 salicylic acid Drugs 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 49
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 47
- 238000002360 preparation method Methods 0.000 description 44
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- 239000002994 raw material Substances 0.000 description 33
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 32
- 239000000843 powder Substances 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 21
- 239000007788 liquid Substances 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 17
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 17
- 230000005764 inhibitory process Effects 0.000 description 17
- SPCXJKWATXURQS-UHFFFAOYSA-N methyl 5-fluoro-2-hydroxy-3-iodobenzoate Chemical compound COC(=O)c1cc(F)cc(I)c1O SPCXJKWATXURQS-UHFFFAOYSA-N 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 14
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- BGMHQBQFJYJLBP-UHFFFAOYSA-N 4-ethynylbenzaldehyde Chemical compound O=CC1=CC=C(C#C)C=C1 BGMHQBQFJYJLBP-UHFFFAOYSA-N 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 11
- 239000007858 starting material Substances 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 108010033040 Histones Proteins 0.000 description 9
- 108091026813 Poly(ADPribose) Proteins 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- 238000010898 silica gel chromatography Methods 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 8
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- PHHRKRGXWSEXFZ-UHFFFAOYSA-N n-(pyridin-3-ylmethyl)-3-[[2-[(2,3,4-trifluorophenoxy)methyl]-1,3-benzoxazol-4-yl]oxy]propan-1-amine Chemical compound FC1=C(F)C(F)=CC=C1OCC(OC1=CC=C2)=NC1=C2OCCCNCC1=CC=CN=C1 PHHRKRGXWSEXFZ-UHFFFAOYSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- HPKJGHVHQWJOOT-ZJOUEHCJSA-N N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide Chemical compound C1C(CCCC1)C[C@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(=O)N[C@@H](C[C@H]1C(=O)NCC1)C=O HPKJGHVHQWJOOT-ZJOUEHCJSA-N 0.000 description 7
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 7
- 229940125941 PARP1/2 inhibitor Drugs 0.000 description 7
- 102100023652 Poly [ADP-ribose] polymerase 2 Human genes 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 101001113440 Homo sapiens Poly [ADP-ribose] polymerase 2 Proteins 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 229950006238 nadide Drugs 0.000 description 6
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 6
- 229960000572 olaparib Drugs 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 description 5
- BQTRMYJYYNQQGK-UHFFFAOYSA-N 1-(bromomethyl)-4-iodobenzene Chemical compound BrCC1=CC=C(I)C=C1 BQTRMYJYYNQQGK-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 102000036365 BRCA1 Human genes 0.000 description 5
- 108700020463 BRCA1 Proteins 0.000 description 5
- 101150072950 BRCA1 gene Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 101001113483 Homo sapiens Poly [ADP-ribose] polymerase 1 Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000033590 base-excision repair Effects 0.000 description 5
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 5
- 230000006801 homologous recombination Effects 0.000 description 5
- 238000002744 homologous recombination Methods 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 108700020462 BRCA2 Proteins 0.000 description 4
- 102000052609 BRCA2 Human genes 0.000 description 4
- 101150008921 Brca2 gene Proteins 0.000 description 4
- SXVOBJSBWKCDNM-UHFFFAOYSA-N C#CC1=CC=C(C[S+]2CCNCC2)C=C1 Chemical compound C#CC1=CC=C(C[S+]2CCNCC2)C=C1 SXVOBJSBWKCDNM-UHFFFAOYSA-N 0.000 description 4
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 239000012661 PARP inhibitor Substances 0.000 description 4
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 229910001873 dinitrogen Inorganic materials 0.000 description 4
- 238000006911 enzymatic reaction Methods 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- RTQTZDAVFZJQJU-UHFFFAOYSA-N methyl 5-fluoro-2-[4-(piperidin-1-ylmethyl)phenyl]-1-benzofuran-7-carboxylate Chemical compound COC(=O)c1cc(F)cc2cc(oc12)-c1ccc(CN2CCCCC2)cc1 RTQTZDAVFZJQJU-UHFFFAOYSA-N 0.000 description 4
- VVXZFRXMJNNWGH-UHFFFAOYSA-N methyl 5-fluoro-2-[4-[(propan-2-ylamino)methyl]phenyl]-1-benzofuran-7-carboxylate Chemical compound COC(=O)c1cc(F)cc2cc(oc12)-c1ccc(CNC(C)C)cc1 VVXZFRXMJNNWGH-UHFFFAOYSA-N 0.000 description 4
- TVLYGKPORJNTBG-UHFFFAOYSA-N n-[(4-ethynylphenyl)methyl]propan-2-amine Chemical compound CC(C)NCC1=CC=C(C#C)C=C1 TVLYGKPORJNTBG-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 3
- JIKBFZGYYOHARZ-UHFFFAOYSA-N 1-(4-ethynyl-3-fluorophenyl)-N-methylmethanamine Chemical compound CNCc1ccc(C#C)c(F)c1 JIKBFZGYYOHARZ-UHFFFAOYSA-N 0.000 description 3
- YHPVLKDFJIKCFM-UHFFFAOYSA-N 1-(4-ethynylphenyl)-n-methylmethanamine Chemical compound CNCC1=CC=C(C#C)C=C1 YHPVLKDFJIKCFM-UHFFFAOYSA-N 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- BLLUCKYTFMZSJB-UHFFFAOYSA-N N-[(4-ethynylphenyl)methyl]cyclopropanamine Chemical compound C#Cc1ccc(CNC2CC2)cc1 BLLUCKYTFMZSJB-UHFFFAOYSA-N 0.000 description 3
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 3
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 231100000225 lethality Toxicity 0.000 description 3
- RSVIRXBNSSRICK-UHFFFAOYSA-N methyl 2-[4-[(cyclopropylamino)methyl]phenyl]-5-fluoro-1-benzofuran-7-carboxylate Chemical compound COC(=O)c1cc(F)cc2cc(oc12)-c1ccc(CNC2CC2)cc1 RSVIRXBNSSRICK-UHFFFAOYSA-N 0.000 description 3
- AEXDUHBLXUNIJF-UHFFFAOYSA-N methyl 2-[4-[(dimethylamino)methyl]phenyl]-5-fluoro-1-benzofuran-7-carboxylate Chemical compound COC(=O)c1cc(F)cc2cc(oc12)-c1ccc(CN(C)C)cc1 AEXDUHBLXUNIJF-UHFFFAOYSA-N 0.000 description 3
- 125000005322 morpholin-1-yl group Chemical group 0.000 description 3
- YRCHYHRCBXNYNU-UHFFFAOYSA-N n-[[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-(4-fluorophenyl)acetamide Chemical compound N1=CC(CNCCOC)=CC=C1C1=CC2=NC=CC(OC=3C(=CC(NC(=S)NC(=O)CC=4C=CC(F)=CC=4)=CC=3)F)=C2S1 YRCHYHRCBXNYNU-UHFFFAOYSA-N 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 102000003702 retinoic acid receptors Human genes 0.000 description 3
- 108090000064 retinoic acid receptors Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 230000005783 single-strand break Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- DIXMBHMNEHPFCX-MCMMXHMISA-N (2r)-2-[5-[6-amino-5-[(1r)-1-[5-fluoro-2-(triazol-2-yl)phenyl]ethoxy]pyridin-3-yl]-4-methyl-1,3-thiazol-2-yl]propane-1,2-diol Chemical compound O([C@H](C)C=1C(=CC=C(F)C=1)N1N=CC=N1)C(C(=NC=1)N)=CC=1C=1SC([C@](C)(O)CO)=NC=1C DIXMBHMNEHPFCX-MCMMXHMISA-N 0.000 description 2
- HPJGEESDHAUUQR-SKGSPYGFSA-N (2s)-2-[[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-1-[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-2-[[(2s)-3-naphthalen-2-yl-2-(3-pyridin-3-ylpropanoylamino)propanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]buta Chemical compound NC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)CCC=1C=NC=CC=1)CC1=CC=CC=C1 HPJGEESDHAUUQR-SKGSPYGFSA-N 0.000 description 2
- KRIWIRSMQRQYJG-DLBZAZTESA-N (2s,3s)-3-[[7-(benzylamino)-3-propan-2-ylpyrazolo[1,5-a]pyrimidin-5-yl]amino]butane-1,2,4-triol Chemical compound C=1C(N[C@@H](CO)[C@H](O)CO)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1 KRIWIRSMQRQYJG-DLBZAZTESA-N 0.000 description 2
- FCHLXMCUBHAYFV-CYBMUJFWSA-N (3R)-N-[(4-ethynylphenyl)methyl]oxolan-3-amine Chemical compound C#Cc1ccc(CN[C@@H]2CCOC2)cc1 FCHLXMCUBHAYFV-CYBMUJFWSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- LPNRUMVKXCLEBE-JXVRESAISA-L (3r)-4-[[(e)-2-[5-ethyl-4-(4-fluorophenyl)-6-phenyl-2-propan-2-ylpyridin-3-yl]ethenyl]-oxidophosphoryl]-3-hydroxybutanoate Chemical compound CCC1=C(C=2C=CC=CC=2)N=C(C(C)C)C(\C=C\P([O-])(=O)C[C@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 LPNRUMVKXCLEBE-JXVRESAISA-L 0.000 description 2
- NUJWKQSEJDYCDB-GNRVTEMESA-N (3s)-1-[(1s,2r,4r)-4-[methyl(propan-2-yl)amino]-2-propylcyclohexyl]-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-2-one Chemical compound CCC[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 NUJWKQSEJDYCDB-GNRVTEMESA-N 0.000 description 2
- DMQYDVBIPXAAJA-VHXPQNKSSA-N (3z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)-(5-methyl-1h-imidazol-2-yl)methylidene]-1h-indol-2-one Chemical compound C1CN(CC)CCC1NC1=CC=C(NC(=O)\C2=C(/C=3NC=C(C)N=3)C=3C=C(F)C=CC=3)C2=C1 DMQYDVBIPXAAJA-VHXPQNKSSA-N 0.000 description 2
- PNHBRYIAJCYNDA-VQCQRNETSA-N (4r)-6-[2-[2-ethyl-4-(4-fluorophenyl)-6-phenylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(CC)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 PNHBRYIAJCYNDA-VQCQRNETSA-N 0.000 description 2
- QVBVQHTXLPNXEY-ZMFCMNQTSA-N (4r)-6-[2-[4-(4-fluorophenyl)-6-phenyl-2-propan-2-ylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(C(C)C)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 QVBVQHTXLPNXEY-ZMFCMNQTSA-N 0.000 description 2
- QOLHWXNSCZGWHK-BWBORTOCSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecylcarbamoyloxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@@H]([C@@H](OC(=O)NCCCCCCCCCCCOC=3C=CC=CC=3)C(O1)(C(O)=O)C(O)(C(O2)C(O)=O)C(O)=O)O)C1=CC=CC=C1 QOLHWXNSCZGWHK-BWBORTOCSA-N 0.000 description 2
- LVHOHZHTZXRVRJ-CMDGGOBGSA-N (e)-3-(3-methoxyphenyl)-n-(3,4,5-trimethoxyphenyl)prop-2-enamide Chemical compound COC1=CC=CC(\C=C\C(=O)NC=2C=C(OC)C(OC)=C(OC)C=2)=C1 LVHOHZHTZXRVRJ-CMDGGOBGSA-N 0.000 description 2
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 2
- DPRJPRMZJGWLHY-HNGSOEQISA-N (e,3r,5s)-7-[5-(4-fluorophenyl)-3-propan-2-yl-1-pyrazin-2-ylpyrazol-4-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound OC(=O)C[C@H](O)C[C@H](O)/C=C/C=1C(C(C)C)=NN(C=2N=CC=NC=2)C=1C1=CC=C(F)C=C1 DPRJPRMZJGWLHY-HNGSOEQISA-N 0.000 description 2
- BSDXIWRSZWFNPU-UHFFFAOYSA-N 1-(4-ethynyl-2-fluorophenyl)-N-methylmethanamine Chemical compound CNCc1ccc(cc1F)C#C BSDXIWRSZWFNPU-UHFFFAOYSA-N 0.000 description 2
- IFXZRANXDFXZPF-UHFFFAOYSA-N 1-(4-ethynylphenyl)-n,n-dimethylmethanamine Chemical compound CN(C)CC1=CC=C(C#C)C=C1 IFXZRANXDFXZPF-UHFFFAOYSA-N 0.000 description 2
- OFXGJTFUMSIQPF-UHFFFAOYSA-N 1-(4-iodophenyl)-n,n-dimethylmethanamine Chemical compound CN(C)CC1=CC=C(I)C=C1 OFXGJTFUMSIQPF-UHFFFAOYSA-N 0.000 description 2
- PKIUBCFWCKZLSV-UHFFFAOYSA-N 1-(4-iodophenyl)-n-methylmethanamine Chemical compound CNCC1=CC=C(I)C=C1 PKIUBCFWCKZLSV-UHFFFAOYSA-N 0.000 description 2
- BUVBAAARUMWMIU-UHFFFAOYSA-N 1-(5-ethynylpyridin-2-yl)-n-methylmethanamine Chemical compound CNCC1=CC=C(C#C)C=N1 BUVBAAARUMWMIU-UHFFFAOYSA-N 0.000 description 2
- BYGDVXJQYGSLTN-UHFFFAOYSA-N 1-(6-ethynylpyridin-3-yl)-n-methylmethanamine Chemical compound CNCC1=CC=C(C#C)N=C1 BYGDVXJQYGSLTN-UHFFFAOYSA-N 0.000 description 2
- FJZNNKJZHQFMCK-LRDDRELGSA-N 1-[(3S,4R)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-phenylurea Chemical compound C1(=CC(=CC(=C1[C@H]1[C@@H](C(=O)NC1)NC(=O)NC1=CC=CC=C1)F)OC)F FJZNNKJZHQFMCK-LRDDRELGSA-N 0.000 description 2
- XIMCFAYSUUEMGV-UHFFFAOYSA-N 1-[(4-ethynylphenyl)methyl]-4-methylpiperazine Chemical compound C1CN(C)CCN1CC1=CC=C(C#C)C=C1 XIMCFAYSUUEMGV-UHFFFAOYSA-N 0.000 description 2
- IDGQATIPUIVKDH-UHFFFAOYSA-N 1-[(4-ethynylphenyl)methyl]piperidine Chemical compound C1=CC(C#C)=CC=C1CN1CCCCC1 IDGQATIPUIVKDH-UHFFFAOYSA-N 0.000 description 2
- ZQPYMFANIVJVKT-UHFFFAOYSA-N 1-[(4-ethynylphenyl)methyl]pyrrolidine Chemical compound C1=CC(C#C)=CC=C1CN1CCCC1 ZQPYMFANIVJVKT-UHFFFAOYSA-N 0.000 description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- YKYWUHHZZRBGMG-JWTNVVGKSA-N 1-methyl-2-[[(1r,5s)-6-[[5-(trifluoromethyl)pyridin-2-yl]methoxymethyl]-3-azabicyclo[3.1.0]hexan-3-yl]methyl]benzimidazole Chemical compound C1([C@@H]2CN(C[C@@H]21)CC=1N(C2=CC=CC=C2N=1)C)COCC1=CC=C(C(F)(F)F)C=N1 YKYWUHHZZRBGMG-JWTNVVGKSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- IVYZDCHNPRWIEN-UHFFFAOYSA-N 2-[4-[(dimethylamino)methyl]phenyl]-5-fluoro-1-benzofuran-7-carboxamide Chemical compound C1=CC(CN(C)C)=CC=C1C1=CC2=CC(F)=CC(C(N)=O)=C2O1 IVYZDCHNPRWIEN-UHFFFAOYSA-N 0.000 description 2
- IKUYUKBRUZAROT-UHFFFAOYSA-N 2-fluoro-4-(2-trimethylsilylethynyl)benzaldehyde Chemical compound C[Si](C)(C)C#CC1=CC=C(C=O)C(F)=C1 IKUYUKBRUZAROT-UHFFFAOYSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical group [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- YLLRPQWLASQXSI-UHFFFAOYSA-N 3-(4b,8a,9,9a-tetrahydro-4aH-pyrido[2,3-b]indol-4-ylamino)phenol Chemical compound Oc1cccc(NC2=CC=NC3NC4C=CC=CC4C23)c1 YLLRPQWLASQXSI-UHFFFAOYSA-N 0.000 description 2
- BFSJOGCDWTZAFP-UHFFFAOYSA-N 3-fluoro-4-(2-trimethylsilylethynyl)benzaldehyde Chemical compound C[Si](C)(C)C#CC1=CC=C(C=O)C=C1F BFSJOGCDWTZAFP-UHFFFAOYSA-N 0.000 description 2
- TXEBWPPWSVMYOA-UHFFFAOYSA-N 4-[3-[(1-amino-2-chloroethyl)amino]propyl]-1-[[3-(2-chlorophenyl)phenyl]methyl]-5-hydroxyimidazolidin-2-one Chemical compound NC(CCl)NCCCC1NC(=O)N(Cc2cccc(c2)-c2ccccc2Cl)C1O TXEBWPPWSVMYOA-UHFFFAOYSA-N 0.000 description 2
- WCDLCPLAAKUJNY-UHFFFAOYSA-N 4-[4-[3-(1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl]phenyl]morpholine Chemical compound C1COCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C2=CNN=C2)C=C1 WCDLCPLAAKUJNY-UHFFFAOYSA-N 0.000 description 2
- SLSHYCVXNLXDGU-UHFFFAOYSA-N 4-ethynyl-2-fluorobenzaldehyde Chemical compound FC1=CC(C#C)=CC=C1C=O SLSHYCVXNLXDGU-UHFFFAOYSA-N 0.000 description 2
- VLYLOYGFKKXKNO-UHFFFAOYSA-N 4-ethynyl-3-fluorobenzaldehyde Chemical compound Fc1cc(C=O)ccc1C#C VLYLOYGFKKXKNO-UHFFFAOYSA-N 0.000 description 2
- JCQNKUBVOFBAJF-UHFFFAOYSA-N 5-(2-trimethylsilylethynyl)pyridine-2-carbaldehyde Chemical compound C[Si](C)(C)C#CC1=CC=C(C=O)N=C1 JCQNKUBVOFBAJF-UHFFFAOYSA-N 0.000 description 2
- KGQQNIMWZHCSCK-UHFFFAOYSA-N 5-ethynylpyridine-2-carbaldehyde Chemical compound O=CC1=CC=C(C#C)C=N1 KGQQNIMWZHCSCK-UHFFFAOYSA-N 0.000 description 2
- MTZVQKHIVINCBV-UHFFFAOYSA-N 5-fluoro-2-[2-fluoro-4-(methylaminomethyl)phenyl]-1-benzofuran-7-carboxamide Chemical compound FC1=CC(CNC)=CC=C1C1=CC2=CC(F)=CC(C(N)=O)=C2O1 MTZVQKHIVINCBV-UHFFFAOYSA-N 0.000 description 2
- PMPWBRWZNPUIKN-UHFFFAOYSA-N 5-fluoro-2-[4-[(propan-2-ylamino)methyl]phenyl]-1-benzofuran-7-carboxamide Chemical compound C1=CC(CNC(C)C)=CC=C1C1=CC2=CC(F)=CC(C(N)=O)=C2O1 PMPWBRWZNPUIKN-UHFFFAOYSA-N 0.000 description 2
- JWPRICQKUNODPZ-UHFFFAOYSA-N 5-fluoro-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC(F)=CC=C1O JWPRICQKUNODPZ-UHFFFAOYSA-N 0.000 description 2
- HPCCNAPRISABKL-UHFFFAOYSA-N 6-(2-trimethylsilylethynyl)pyridine-3-carbaldehyde Chemical compound C[Si](C)(C)C#CC1=CC=C(C=O)C=N1 HPCCNAPRISABKL-UHFFFAOYSA-N 0.000 description 2
- RRELDGDKULRRDM-UHFFFAOYSA-N 6-[2-chloro-4-nitro-5-(oxan-4-yloxy)anilino]-3,4-dihydro-1H-quinolin-2-one Chemical compound [O-][N+](=O)c1cc(Cl)c(Nc2ccc3NC(=O)CCc3c2)cc1OC1CCOCC1 RRELDGDKULRRDM-UHFFFAOYSA-N 0.000 description 2
- MTGHDMSHFPXRNT-UHFFFAOYSA-N 6-ethynylpyridine-3-carbaldehyde Chemical compound O=CC1=CC=C(C#C)N=C1 MTGHDMSHFPXRNT-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- QCMHGCDOZLWPOT-FMNCTDSISA-N COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 Chemical compound COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 QCMHGCDOZLWPOT-FMNCTDSISA-N 0.000 description 2
- 229940126559 Compound 4e Drugs 0.000 description 2
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NINVWUVVSVOPDI-UHFFFAOYSA-N N,N-dimethyl-1-[4-(2-trimethylsilylethynyl)phenyl]methanamine Chemical compound CN(C)Cc1ccc(cc1)C#C[Si](C)(C)C NINVWUVVSVOPDI-UHFFFAOYSA-N 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102100037664 Poly [ADP-ribose] polymerase tankyrase-1 Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102100034931 Protein mono-ADP-ribosyltransferase PARP4 Human genes 0.000 description 2
- 108010091086 Recombinases Proteins 0.000 description 2
- 102000018120 Recombinases Human genes 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 229940125907 SJ995973 Drugs 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 230000000274 adsorptive effect Effects 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000012830 cancer therapeutic Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- AEULIVPVIDOLIN-UHFFFAOYSA-N cep-11981 Chemical compound C1=C2C3=C4CNC(=O)C4=C4C5=CN(C)N=C5CCC4=C3N(CC(C)C)C2=CC=C1NC1=NC=CC=N1 AEULIVPVIDOLIN-UHFFFAOYSA-N 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940127206 compound 14d Drugs 0.000 description 2
- 229940125872 compound 4d Drugs 0.000 description 2
- 229940126115 compound 4f Drugs 0.000 description 2
- 229940125880 compound 4j Drugs 0.000 description 2
- 150000001907 coumarones Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000001177 diphosphate Substances 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 230000005782 double-strand break Effects 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 102000049595 human PARP1 Human genes 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- ROBJKLPZIPNAMV-UHFFFAOYSA-N mefuparib Chemical compound C1=CC(CNC)=CC=C1C1=CC2=CC(F)=CC(C(N)=O)=C2O1 ROBJKLPZIPNAMV-UHFFFAOYSA-N 0.000 description 2
- HJWOQGPSXOQKCI-UHFFFAOYSA-N methyl 3-chloro-2-[4-[(dimethylamino)methyl]phenyl]-5-fluoro-1-benzofuran-7-carboxylate Chemical compound COC(=O)c1cc(F)cc2c(Cl)c(oc12)-c1ccc(CN(C)C)cc1 HJWOQGPSXOQKCI-UHFFFAOYSA-N 0.000 description 2
- BLYMUYQRQBBAIA-UHFFFAOYSA-N methyl 5-fluoro-2-[4-(methylaminomethyl)phenyl]-1-benzofuran-7-carboxylate Chemical compound CNCc1ccc(cc1)-c1cc2cc(F)cc(C(=O)OC)c2o1 BLYMUYQRQBBAIA-UHFFFAOYSA-N 0.000 description 2
- QSNXTXKQJFQWEL-UHFFFAOYSA-N methyl 5-fluoro-2-[4-(pyrrolidin-1-ylmethyl)phenyl]-1-benzofuran-7-carboxylate Chemical compound COC(=O)c1cc(F)cc2cc(oc12)-c1ccc(CN2CCCC2)cc1 QSNXTXKQJFQWEL-UHFFFAOYSA-N 0.000 description 2
- BTJBCZMGCQJDIN-UHFFFAOYSA-N methyl 5-fluoro-2-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-1-benzofuran-7-carboxylate Chemical compound COC(=O)c1cc(F)cc2cc(oc12)-c1ccc(CN2CCN(C)CC2)cc1 BTJBCZMGCQJDIN-UHFFFAOYSA-N 0.000 description 2
- MIMKIFPCDUEQTL-UHFFFAOYSA-N methyl 5-fluoro-2-[6-(methylaminomethyl)pyridin-3-yl]-1-benzofuran-7-carboxylate Chemical compound CNCc1ccc(cn1)-c1cc2cc(F)cc(C(=O)OC)c2o1 MIMKIFPCDUEQTL-UHFFFAOYSA-N 0.000 description 2
- DGHBWVVOJLVMFF-UHFFFAOYSA-N methyl 5-fluoro-2-hydroxybenzoate Chemical compound COC(=O)C1=CC(F)=CC=C1O DGHBWVVOJLVMFF-UHFFFAOYSA-N 0.000 description 2
- KQNYTTDHCMFOME-UHFFFAOYSA-N methyl n-[[3-[(4-tert-butylpiperazin-1-yl)methyl]-8-fluoro-2-phenylquinoline-4-carbonyl]amino]-n-phenylcarbamate Chemical compound C=1C=CC=CC=1N(C(=O)OC)NC(=O)C(C1=CC=CC(F)=C1N=C1C=2C=CC=CC=2)=C1CN1CCN(C(C)(C)C)CC1 KQNYTTDHCMFOME-UHFFFAOYSA-N 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 2
- DOWVMJFBDGWVML-UHFFFAOYSA-N n-cyclohexyl-n-methyl-4-(1-oxidopyridin-1-ium-3-yl)imidazole-1-carboxamide Chemical compound C1=NC(C=2C=[N+]([O-])C=CC=2)=CN1C(=O)N(C)C1CCCCC1 DOWVMJFBDGWVML-UHFFFAOYSA-N 0.000 description 2
- IQNUPRBMYCMWIG-UHFFFAOYSA-N n-methyl-1-[4-(2-trimethylsilylethynyl)phenyl]methanamine Chemical compound CNCC1=CC=C(C#C[Si](C)(C)C)C=C1 IQNUPRBMYCMWIG-UHFFFAOYSA-N 0.000 description 2
- 230000006780 non-homologous end joining Effects 0.000 description 2
- 230000020520 nucleotide-excision repair Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 238000009521 phase II clinical trial Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 2
- 230000003007 single stranded DNA break Effects 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FRACPXUHUTXLCX-BELIEFIBSA-N tert-butyl N-{1-[(1S)-1-{[(1R,2S)-1-(benzylcarbamoyl)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}-2-cyclopropylethyl]-2-oxopyridin-3-yl}carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CN(C1=O)[C@@H](CC2CC2)C(=O)N[C@@H](C[C@@H]3CCNC3=O)[C@H](C(=O)NCC4=CC=CC=C4)O FRACPXUHUTXLCX-BELIEFIBSA-N 0.000 description 2
- ZXCUOCHXNYWBBG-ZQWQDMLBSA-N (1s,2s,3s,4s)-3,4-bis[2-methylpropyl-[(4-phenoxyphenyl)methyl]carbamoyl]cyclobutane-1,2-dicarboxylic acid Chemical compound O=C([C@H]1[C@@H]([C@@H]([C@H]1C(O)=O)C(O)=O)C(=O)N(CC(C)C)CC=1C=CC(OC=2C=CC=CC=2)=CC=1)N(CC(C)C)CC(C=C1)=CC=C1OC1=CC=CC=C1 ZXCUOCHXNYWBBG-ZQWQDMLBSA-N 0.000 description 1
- GNPHAOQLHRZODS-ZQWQDMLBSA-N (1s,2s,3s,4s)-3,4-bis[butyl-[(4-phenoxyphenyl)methyl]carbamoyl]cyclobutane-1,2-dicarboxylic acid Chemical compound O=C([C@H]1[C@@H]([C@@H]([C@H]1C(O)=O)C(O)=O)C(=O)N(CCCC)CC=1C=CC(OC=2C=CC=CC=2)=CC=1)N(CCCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 GNPHAOQLHRZODS-ZQWQDMLBSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- MIPHRQMEIYLZFZ-SCSAIBSYSA-N (3r)-oxolan-3-amine Chemical compound N[C@@H]1CCOC1 MIPHRQMEIYLZFZ-SCSAIBSYSA-N 0.000 description 1
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- OLOHEKLZHBXCOU-UHFFFAOYSA-N 1-[(4-ethynylphenyl)methyl]-4-methyl-1,4-diazepane Chemical compound CN1CCCN(Cc2ccc(cc2)C#C)CC1 OLOHEKLZHBXCOU-UHFFFAOYSA-N 0.000 description 1
- AHZCYZMNFBGXAC-UHFFFAOYSA-N 1-[[5-chloro-2-(trifluoromethyl)phenyl]methyl]-7-(2-piperazin-1-ylpyridin-4-yl)-3,4-dihydro-2h-pyrido[2,3-b]pyrazine Chemical compound FC(F)(F)C1=CC=C(Cl)C=C1CN1C2=CC(C=3C=C(N=CC=3)N3CCNCC3)=CN=C2NCC1 AHZCYZMNFBGXAC-UHFFFAOYSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- FXHRAKUEZPSMLJ-UHFFFAOYSA-N 1-methyl-1,4-diazepane Chemical compound CN1CCCNCC1 FXHRAKUEZPSMLJ-UHFFFAOYSA-N 0.000 description 1
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
- JGMXNNSYEFOBHQ-OWOJBTEDSA-N 2-[(e)-4-morpholin-4-ylbut-2-enyl]-1,1-dioxothieno[3,2-e]thiazine-6-sulfonamide Chemical compound O=S1(=O)C=2SC(S(=O)(=O)N)=CC=2C=CN1C\C=C\CN1CCOCC1 JGMXNNSYEFOBHQ-OWOJBTEDSA-N 0.000 description 1
- ORQHHLPTMSGMQT-UHFFFAOYSA-N 2-[4-(5-fluoropyridin-2-yl)piperazin-1-yl]-n-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide Chemical compound N1=CC(F)=CC=C1N1CCN(CC(=O)NC=2SC=3CCCCC=3N=2)CC1 ORQHHLPTMSGMQT-UHFFFAOYSA-N 0.000 description 1
- MPRWIWBWKXZIBF-UHFFFAOYSA-N 2-[4-[(cyclopropylamino)methyl]phenyl]-5-fluoro-1-benzofuran-7-carboxamide Chemical compound O1C=2C(C(=O)N)=CC(F)=CC=2C=C1C(C=C1)=CC=C1CNC1CC1 MPRWIWBWKXZIBF-UHFFFAOYSA-N 0.000 description 1
- JGTKZBLODHTFKS-UHFFFAOYSA-N 2-[4-[(dimethylamino)methyl]phenyl]-5-fluoro-1-benzofuran-7-carboxamide hydrochloride Chemical compound Cl.CN(C)Cc1ccc(cc1)-c1cc2cc(F)cc(C(N)=O)c2o1 JGTKZBLODHTFKS-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
- ZHKWEYUNKQUHGQ-UHFFFAOYSA-N 3-chloro-2-[4-[(dimethylamino)methyl]phenyl]-5-fluoro-1-benzofuran-7-carboxamide Chemical compound C1=CC(CN(C)C)=CC=C1C1=C(Cl)C2=CC(F)=CC(C(N)=O)=C2O1 ZHKWEYUNKQUHGQ-UHFFFAOYSA-N 0.000 description 1
- CGQJITDLUBMLFF-UHFFFAOYSA-N 3-fluoro-4-iodobenzaldehyde Chemical compound FC1=CC(C=O)=CC=C1I CGQJITDLUBMLFF-UHFFFAOYSA-N 0.000 description 1
- XDCOYBQVEVSNNB-UHFFFAOYSA-N 4-[(7-naphthalen-2-yl-1-benzothiophen-2-yl)methylamino]butanoic acid Chemical compound OC(=O)CCCNCc1cc2cccc(-c3ccc4ccccc4c3)c2s1 XDCOYBQVEVSNNB-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- SWHUROFMIMHWKS-UHFFFAOYSA-N 4-bromo-3-fluorobenzaldehyde Chemical compound FC1=CC(C=O)=CC=C1Br SWHUROFMIMHWKS-UHFFFAOYSA-N 0.000 description 1
- ZRYZBQLXDKPBDU-UHFFFAOYSA-N 4-bromobenzaldehyde Chemical compound BrC1=CC=C(C=O)C=C1 ZRYZBQLXDKPBDU-UHFFFAOYSA-N 0.000 description 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
- ZQVLPMNLLKGGIU-UHFFFAOYSA-N 5-bromopyridine-2-carbaldehyde Chemical compound BrC1=CC=C(C=O)N=C1 ZQVLPMNLLKGGIU-UHFFFAOYSA-N 0.000 description 1
- ISAUBHFLGQRFOW-UHFFFAOYSA-N 5-fluoro-2-[2-fluoro-4-(methylaminomethyl)phenyl]-1-benzofuran-7-carboxylic acid Chemical compound CNCC1=CC(=C(C=C1)C2=CC3=CC(=CC(=C3O2)C(=O)O)F)F ISAUBHFLGQRFOW-UHFFFAOYSA-N 0.000 description 1
- RCRMVNPHKQGCMA-UHFFFAOYSA-N 5-fluoro-2-[3-fluoro-4-(methylaminomethyl)phenyl]-1-benzofuran-7-carboxamide Chemical compound C1=C(F)C(CNC)=CC=C1C1=CC2=CC(F)=CC(C(N)=O)=C2O1 RCRMVNPHKQGCMA-UHFFFAOYSA-N 0.000 description 1
- UVFDPMNFQWNEKD-UHFFFAOYSA-N 5-fluoro-2-[3-fluoro-4-(methylaminomethyl)phenyl]-1-benzofuran-7-carboxylic acid Chemical compound CNCC1=C(C=C(C=C1)C2=CC3=CC(=CC(=C3O2)C(=O)O)F)F UVFDPMNFQWNEKD-UHFFFAOYSA-N 0.000 description 1
- XLUZJVIPGFBRGS-UHFFFAOYSA-N 5-fluoro-2-[4-(piperidin-1-ylmethyl)phenyl]-1-benzofuran-7-carboxamide Chemical compound O1C=2C(C(=O)N)=CC(F)=CC=2C=C1C(C=C1)=CC=C1CN1CCCCC1 XLUZJVIPGFBRGS-UHFFFAOYSA-N 0.000 description 1
- LHTKHVZGMWZICX-UHFFFAOYSA-N 5-fluoro-2-[4-(pyrrolidin-1-ylmethyl)phenyl]-1-benzofuran-7-carboxamide Chemical compound O1C=2C(C(=O)N)=CC(F)=CC=2C=C1C(C=C1)=CC=C1CN1CCCC1 LHTKHVZGMWZICX-UHFFFAOYSA-N 0.000 description 1
- HPRGIBRDBMAZAX-UHFFFAOYSA-N 5-fluoro-2-[4-(pyrrolidin-1-ylmethyl)phenyl]-1-benzofuran-7-carboxylic acid Chemical compound C1CCN(C1)CC2=CC=C(C=C2)C3=CC4=CC(=CC(=C4O3)C(=O)O)F HPRGIBRDBMAZAX-UHFFFAOYSA-N 0.000 description 1
- VMRFZHUKMSGCTI-UHFFFAOYSA-N 5-fluoro-2-[4-[(4-methyl-1,4-diazepan-1-yl)methyl]phenyl]-1-benzofuran-7-carboxamide Chemical compound C1CN(C)CCCN1CC1=CC=C(C=2OC3=C(C(N)=O)C=C(F)C=C3C=2)C=C1 VMRFZHUKMSGCTI-UHFFFAOYSA-N 0.000 description 1
- IBUGAAZQRSXLKA-UHFFFAOYSA-N 5-fluoro-2-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-1-benzofuran-7-carboxamide Chemical compound C1CN(C)CCN1CC1=CC=C(C=2OC3=C(C(N)=O)C=C(F)C=C3C=2)C=C1 IBUGAAZQRSXLKA-UHFFFAOYSA-N 0.000 description 1
- BQWQSOZIHDTTMO-UHFFFAOYSA-N 5-fluoro-2-[4-[(piperidin-4-ylamino)methyl]phenyl]-1-benzofuran-7-carboxamide Chemical compound O1C=2C(C(=O)N)=CC(F)=CC=2C=C1C(C=C1)=CC=C1CNC1CCNCC1 BQWQSOZIHDTTMO-UHFFFAOYSA-N 0.000 description 1
- WJKYDRMLYGPVOU-MRXNPFEDSA-N 5-fluoro-2-[4-[[[(3R)-oxolan-3-yl]amino]methyl]phenyl]-1-benzofuran-7-carboxylic acid Chemical compound OC(=O)c1cc(F)cc2cc(oc12)-c1ccc(CN[C@@H]2CCOC2)cc1 WJKYDRMLYGPVOU-MRXNPFEDSA-N 0.000 description 1
- WXCWWBKFDYMDBT-MRXNPFEDSA-N 5-fluoro-2-[4-[[[(3r)-oxolan-3-yl]amino]methyl]phenyl]-1-benzofuran-7-carboxamide Chemical compound O1C=2C(C(=O)N)=CC(F)=CC=2C=C1C(C=C1)=CC=C1CN[C@@H]1CCOC1 WXCWWBKFDYMDBT-MRXNPFEDSA-N 0.000 description 1
- AYHGXVGQFXBXKW-UHFFFAOYSA-N 5-fluoro-2-[5-(methylaminomethyl)pyridin-2-yl]-1-benzofuran-7-carboxamide Chemical compound N1=CC(CNC)=CC=C1C1=CC2=CC(F)=CC(C(N)=O)=C2O1 AYHGXVGQFXBXKW-UHFFFAOYSA-N 0.000 description 1
- NIYGCGJWJZNRHE-UHFFFAOYSA-N 5-fluoro-2-[5-(methylaminomethyl)pyridin-2-yl]-1-benzofuran-7-carboxylic acid Chemical compound CNCC1=CN=C(C=C1)C2=CC3=CC(=CC(=C3O2)C(=O)O)F NIYGCGJWJZNRHE-UHFFFAOYSA-N 0.000 description 1
- RTDFVVYBJNJWMG-UHFFFAOYSA-N 5-fluoro-2-[6-(methylaminomethyl)pyridin-3-yl]-1-benzofuran-7-carboxamide Chemical compound C1=NC(CNC)=CC=C1C1=CC2=CC(F)=CC(C(N)=O)=C2O1 RTDFVVYBJNJWMG-UHFFFAOYSA-N 0.000 description 1
- PVUKGNBRJFTFNJ-UHFFFAOYSA-N 6-bromopyridine-3-carbaldehyde Chemical compound BrC1=CC=C(C=O)C=N1 PVUKGNBRJFTFNJ-UHFFFAOYSA-N 0.000 description 1
- UFMQJYHLIUACCG-UHFFFAOYSA-N 8-nitroindolo[2,1-b]quinazoline-6,12-dione Chemical compound C1=CC=C2C(=O)N3C4=CC=C([N+](=O)[O-])C=C4C(=O)C3=NC2=C1 UFMQJYHLIUACCG-UHFFFAOYSA-N 0.000 description 1
- 102000009062 ADP Ribose Transferases Human genes 0.000 description 1
- 108010049290 ADP Ribose Transferases Proteins 0.000 description 1
- PWJFNRJRHXWEPT-UHFFFAOYSA-N ADP ribose Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)C=O)C(O)C1O PWJFNRJRHXWEPT-UHFFFAOYSA-N 0.000 description 1
- SRNWOUGRCWSEMX-TYASJMOZSA-N ADP-D-ribose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1OC(O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-TYASJMOZSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- WZIWDPMOBJMLTG-UHFFFAOYSA-N C(#C)C1=CC=C(CNC2CCN(CC2)C(=O)O)C=C1 Chemical compound C(#C)C1=CC=C(CNC2CCN(CC2)C(=O)O)C=C1 WZIWDPMOBJMLTG-UHFFFAOYSA-N 0.000 description 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 1
- FRSDVPVBDSOWEL-UHFFFAOYSA-N C1CC1NCC2=CC=C(C=C2)C3=CC4=CC(=CC(=C4O3)C(=O)O)F Chemical compound C1CC1NCC2=CC=C(C=C2)C3=CC4=CC(=CC(=C4O3)C(=O)O)F FRSDVPVBDSOWEL-UHFFFAOYSA-N 0.000 description 1
- YTZRYQRZMFWEEI-QGZVFWFLSA-N COC(=O)c1cc(F)cc2cc(oc12)-c1ccc(CN[C@@H]2CCOC2)cc1 Chemical compound COC(=O)c1cc(F)cc2cc(oc12)-c1ccc(CN[C@@H]2CCOC2)cc1 YTZRYQRZMFWEEI-QGZVFWFLSA-N 0.000 description 1
- ZEZNMNUYFBQSOT-UHFFFAOYSA-N COC(C1=CC(F)=CC2=C1OC(C1=CC=C(C[S+]3CCNCC3)C=C1)=C2)=O Chemical compound COC(C1=CC(F)=CC2=C1OC(C1=CC=C(C[S+]3CCNCC3)C=C1)=C2)=O ZEZNMNUYFBQSOT-UHFFFAOYSA-N 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 125000000824 D-ribofuranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@]1([H])O[H] 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 231100001074 DNA strand break Toxicity 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000663006 Homo sapiens Poly [ADP-ribose] polymerase tankyrase-1 Proteins 0.000 description 1
- 101000735456 Homo sapiens Protein mono-ADP-ribosyltransferase PARP3 Proteins 0.000 description 1
- 101000735463 Homo sapiens Protein mono-ADP-ribosyltransferase PARP4 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- TZCCKCLHNUSAMQ-DUGSHLAESA-N NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N Chemical compound NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N TZCCKCLHNUSAMQ-DUGSHLAESA-N 0.000 description 1
- PNXHASMWDJTFGN-UHFFFAOYSA-O NC(C1=CC(F)=CC2=C1OC(C1=CC=C(C[S+]3CCNCC3)C=C1)=C2)=O Chemical compound NC(C1=CC(F)=CC2=C1OC(C1=CC=C(C[S+]3CCNCC3)C=C1)=C2)=O PNXHASMWDJTFGN-UHFFFAOYSA-O 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- AKQOBHZKBDHWQI-BZEFIUHZSA-N O[C@H]1C[C@@H](CCC1)N1C(C2(C3=C1N=C(N=C3)NC1=CC=C(C=C1)S(=O)(=O)NC([2H])([2H])[2H])CC2)=O Chemical compound O[C@H]1C[C@@H](CCC1)N1C(C2(C3=C1N=C(N=C3)NC1=CC=C(C=C1)S(=O)(=O)NC([2H])([2H])[2H])CC2)=O AKQOBHZKBDHWQI-BZEFIUHZSA-N 0.000 description 1
- 241000219830 Onobrychis Species 0.000 description 1
- 241001666355 Persea obovatifolia Species 0.000 description 1
- 101710144590 Poly [ADP-ribose] polymerase 2 Proteins 0.000 description 1
- 101710129670 Poly [ADP-ribose] polymerase tankyrase-1 Proteins 0.000 description 1
- 102100037477 Poly [ADP-ribose] polymerase tankyrase-2 Human genes 0.000 description 1
- 101710129674 Poly [ADP-ribose] polymerase tankyrase-2 Proteins 0.000 description 1
- 102000008866 Prostaglandin E receptors Human genes 0.000 description 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 description 1
- 102100034935 Protein mono-ADP-ribosyltransferase PARP3 Human genes 0.000 description 1
- 101710204725 Protein mono-ADP-ribosyltransferase PARP4 Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 235000005811 Viola adunca Nutrition 0.000 description 1
- 240000009038 Viola odorata Species 0.000 description 1
- 235000013487 Viola odorata Nutrition 0.000 description 1
- 235000002254 Viola papilionacea Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- HYVHMMMLUBHJIQ-UHFFFAOYSA-N [O-]C(C1=CC(F)=CC2=C1OC(C1=CC=C(C[S+]3CCNCC3)C=C1)=C2)=O Chemical compound [O-]C(C1=CC(F)=CC2=C1OC(C1=CC=C(C[S+]3CCNCC3)C=C1)=C2)=O HYVHMMMLUBHJIQ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- MOOAHMCRPCTRLV-UHFFFAOYSA-N boron sodium Chemical compound [B].[Na] MOOAHMCRPCTRLV-UHFFFAOYSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 230000006364 cellular survival Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940127108 compound 5g Drugs 0.000 description 1
- 229940126136 compound 5i Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000012361 double-strand break repair Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- VOLZBKQSLGCZGC-UHFFFAOYSA-N egonol Chemical class C1=C2OCOC2=CC(C2=CC=3C=C(CCCO)C=C(C=3O2)OC)=C1 VOLZBKQSLGCZGC-UHFFFAOYSA-N 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- YWKVMGDEOUPQGN-UHFFFAOYSA-N ethyl 2-[4-[2-(3-hydroxy-1-azabicyclo[2.2.2]octan-3-yl)ethynyl]phenyl]acetate Chemical compound C1=CC(CC(=O)OCC)=CC=C1C#CC1(O)C(CC2)CCN2C1 YWKVMGDEOUPQGN-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000008531 maintenance mechanism Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- GPFWTAVHQKERKY-UHFFFAOYSA-N mefuparib hydrochloride Chemical compound Cl.CNCc1ccc(cc1)-c1cc2cc(F)cc(C(N)=O)c2o1 GPFWTAVHQKERKY-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- YURIIXGLFQWADJ-UHFFFAOYSA-N methyl 5-fluoro-2-[2-fluoro-4-(methylaminomethyl)phenyl]-1-benzofuran-7-carboxylate Chemical compound CNCc1ccc(-c2cc3cc(F)cc(C(=O)OC)c3o2)c(F)c1 YURIIXGLFQWADJ-UHFFFAOYSA-N 0.000 description 1
- CZYDWPDEZKVTMX-UHFFFAOYSA-N methyl 5-fluoro-2-[3-fluoro-4-(methylaminomethyl)phenyl]-1-benzofuran-7-carboxylate Chemical compound CNCc1ccc(cc1F)-c1cc2cc(F)cc(C(=O)OC)c2o1 CZYDWPDEZKVTMX-UHFFFAOYSA-N 0.000 description 1
- LMENKTJXOWUJDP-UHFFFAOYSA-N methyl 5-fluoro-2-[4-[(4-methyl-1,4-diazepan-1-yl)methyl]phenyl]-1-benzofuran-7-carboxylate Chemical compound COC(=O)c1cc(F)cc2cc(oc12)-c1ccc(CN2CCCN(C)CC2)cc1 LMENKTJXOWUJDP-UHFFFAOYSA-N 0.000 description 1
- QDKFJOUHEXZBFQ-UHFFFAOYSA-N methyl 5-fluoro-2-[5-(methylaminomethyl)pyridin-2-yl]-1-benzofuran-7-carboxylate Chemical compound CNCc1ccc(nc1)-c1cc2cc(F)cc(C(=O)OC)c2o1 QDKFJOUHEXZBFQ-UHFFFAOYSA-N 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- FYFFGSSZFBZTAH-UHFFFAOYSA-N methylaminomethanetriol Chemical compound CNC(O)(O)O FYFFGSSZFBZTAH-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- JBLLRCOZJMVOAE-HSQYWUDLSA-N n-[(2s)-1-[[(2s)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-4-methoxy-1h-indole-2-carboxamide Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)C=1NC=2C=CC=C(C=2C=1)OC)C(=O)C=1SC2=CC=CC=C2N=1)[C@@H]1CCNC1=O JBLLRCOZJMVOAE-HSQYWUDLSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 150000005480 nicotinamides Chemical class 0.000 description 1
- 230000004987 nonapoptotic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000033443 single strand break repair Effects 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- OESFSXYRSCBAQJ-UHFFFAOYSA-M sodium;3-carboxy-3,5-dihydroxy-5-oxopentanoate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC([O-])=O OESFSXYRSCBAQJ-UHFFFAOYSA-M 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- WGRQANOPCQRCME-PMACEKPBSA-N teneligliptin Chemical compound O=C([C@H]1NC[C@H](C1)N1CCN(CC1)C1=CC(=NN1C=1C=CC=CC=1)C)N1CCSC1 WGRQANOPCQRCME-PMACEKPBSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000003744 tubulin modulator Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/08—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/307—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of halogen; by substitution of halogen atoms by other halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
R1およびR2は、それぞれ独立に水素、C1-C4の直鎖もしくは分枝鎖のアルキル基、C3-C4のシクロアルキル基または酸素もしくは窒素を含有する飽和の5員もしくは6員の複素環基で、
あるいは、R1およびR2は、Nと一緒になって少なくとも一つのヘテロ原子を含有する無置換もしくは置換の飽和の5員もしくは6員の複素環基を形成し、ここで、前記ヘテロ原子はO、NおよびSで、前記置換基はNにあるメチル基で、
R3は、水素原子または塩素原子で、
R4は、水素原子またはフッ素原子で、
Xは、CH、CFまたはNで、
Yは、CH、CFまたはNである。
R1は、水素、メチル基、エチル基、イソプロピル基、シクロプロピル基、ピペリジン-4-イル基または(R)テトラヒドロフラン-3-イル基で、
R2は、水素、メチル基、エチル基、イソプロピル基、シクロプロピル基、ピペリジン-4-イル基または(R)テトラヒドロフラン-3-イル基で、
あるいは、R1およびR2は、無置換もしくは置換の、モルホリル基、ピペラジル基、ホモピペラジル基、チオモルホリル基、ピペリジル基またはピロリジル基を形成し、ここで、前記置換基はNにあるメチル基で、
R3は、水素原子で、
R4は、フッ素原子で、
Xは、CH、CFまたはNで、
Yは、CH、CFまたはNである。
R1は、水素またはメチル基で、
R2は、メチル基、イソプロピル基、シクロプロピル基、ピペリジン-4-イル基または(R)テトラヒドロフラン-3-イル基で、
あるいは、R1およびR2は、無置換もしくは置換の、モルホリル基、ピペラジル基、ホモピペラジル基、チオモルホリル基、ピペリジル基またはピロリジル基を形成し、ここで、前記置換基はNにあるメチル基で、
R3は、水素原子で、
R4は、フッ素原子で、
Xは、CH、CFまたはNで、
Yは、CH、CFまたはNである。
本発明のもう一つの目的は、合成経路が
a)5-位置換のサリチル酸1をエステル化反応させて化合物2を生成する工程と、
b)化合物2をヨウ素化反応させて化合物3を生成する工程と、
c)化合物3と置換芳香族アルキン化合物8を薗頭反応させ、閉環して化合物4を生成する工程と、
d)化合物4をハロゲン化反応させて化合物6を生成する工程と、
e)化合物4または化合物6をアンモノリシス反応させてそれぞれ化合物5または化合物I(または7)を生成する工程と、
を含むスキーム1で示される、一般式Iで表される化合物の製造方法を提供する。
前述工程b)の条件は、N,N-ジメチルホルムアミドを溶媒とし、薄層クロマトグラフィーの検出で反応が完成するまで、N-ヨードスクシンイミドと窒素ガスの保護下で室温で撹拌することである。
前述工程e)の条件は、アンモニアの飽和メタノール溶液を溶媒とし、封じて70〜120℃で一晩反応させることであるが、直接濃アンモニア水と封じて70〜120℃で一晩撹拌して反応させてもよい。
f) 化合物9をアミン置換反応させて化合物10を生成する工程と、
g)化合物10または化合物12を園頭反応させてそれぞれ化合物11または化合物13を生成する工程と、
h)化合物11または化合物13を脱保護基させてそれぞれ化合物8または化合物14を生成する工程と、
i)化合物14を還元アミン化して化合物8を生成する工程と、
を含む以下の経路1または経路2で示される、異なる置換芳香族アルキン化合物8の製造方法を提供する。
前述工程g)の条件は、テトラヒドロフランを溶媒とし、ビス(トリフェニルホスフィン)パラジウムジクロリド、ヨウ化第一銅を触媒とし、ジイソプロピルエチルアミンを塩基とし、窒素ガスの保護下でトリメチルシリルアセチレンと還流させることである。
前述工程i)の条件は、メタノールを溶媒とし、シアノ水素化ホウ素ナトリウムを還元剤とし、異なるアミンと室温で撹拌して反応させることである。
ここで、R1、R2、XおよびYの定義は、上述の通りである。
以下、実施例によって本発明に係る化合物の構造と製造方法および体内外のPARP1/2阻害活性をさらに説明するが、本発明はこれらの説明に制限される。
全ての実施例において、5-フルオロサリチル酸は上海卒得(書亜)医薬科技有限公司によって、ビス(トリフェニルホスフィン)パラジウムジクロリドはShanghai Chiral Chemistry Co., Ltdによって、トリメチルシリルアセチレンは大連化工研究設計院によって、4-ブロモベンズアルデヒドは上海邦成化工有限公司によって、N-ヨードスクシンイミドは上海進瑞化学有限公司によって、特に説明しない限り、他の開始試薬、溶媒、材料はいずれも国薬試薬グループによって提供された。
NBS N-ブロモスクシンイミド
NIS N-ヨードスクシンイミド
NCS N-クロロスクシンイミド
DMF N,N-ジメチルホルムアミド
DIPEA ジイソプロピルエチルアミン
THF テトラヒドロフラン
実施例1
5-フルオロサリチル酸メチル(化合物2a)の製造:
1HNMR (300 MHz, CDCl3) δ 10.51 (s, 1H), 7.50 (dd, J = 3.3, 8.7 Hz, 1H), 7.22-7.15 (m,1H), 6.94 (q, J = 4.5Hz, 1H), 3.96 (s, 3H); MS (EI) M+:m/z (%) 170 (50)。
1H-NMR (300 MHz, CDCl3) δ 11.37 (s, 1H), 7.70 (dd, J = 3.3, 7.8 Hz, 1H), 7.56 (dd, J = 3.3, 8.7 Hz, 1H), 3.98 (s, 3H); MS (ESI) (M+H)+: m/z (%) 297.0 (55)。
N,N-ジメチル-1-(4-ヨードフェニル)メチルアミン(化合物10a)の製造:
1HNMR (300 MHz, CDCl3) δ 7.63 (d, J = 8.1 Hz, 2H), 7.05 (d, J = 8.1 Hz, 2H), 3.35 (s, 2H), 2.22 (s, 6H); MS (ESI) (M+H)+: m/z (%) 262.0 (100)。
1HNMR (300 MHz, CDCl3) δ 7.44 (d, J = 8.1 Hz, 2H), 7.22 (d, J = 8.1 Hz, 2H), 3.39 (s, 2H), 2.21 (s, 6H) , 0.24 (s, 9H); MS (ESI) (M+H)+: m/z (%) 232.0 (100)。
1HNMR (300 MHz, CDCl3) δ 7.46 (d, J = 8.1 Hz, 2H), 7.25 (d, J = 8.1 Hz, 2H), 3.40 (s, 2H), 3.05 (s, 1H),2.21 (s, 6H); MS (ESI) (M+H)+: m/z (%) 160.2 (100)。
1HNMR (300 MHz, CDCl3) δ 7.90 (d, J = 8.7 Hz, 2H), 7.64 (dd, J = 3.0, 9.3 Hz, 1H), 7.54 (d, J = 8.1 Hz, 2H), 7.43 (dd, J = 3.0, 8.1 Hz, 1H), 7.04 (s, 1H), 4.05 (s, 3H), 3.73 (s, 2H), 2.44 (s, 6H); MS (ESI) (M+H)+: m/z (%) 328.2 (100)。
1HNMR (300 MHz, d6-DMSO) δ 7.98-7.60 (m, 3H), 7.89 (br s, 1H), 7.66 (dd, J = 3.0, 8.7 Hz, 1H), 7.49-7.43 (m, 4H), 3.45 (s, 2H),2.17 (s, 6H); MS (ESI) (M+H)+: m/z (%) 313.2 (100)。
N-メチル-1-(4-ヨードフェニル)メチルアミン(化合物10b)の製造:
1HNMR (300 MHz, CDCl3) δ 7.63 (d, J = 8.1 Hz, 2H), 7.06 (d, J = 8.1 Hz, 2H), 3.68 (s, 2H), 2.43 (s, 3H);MS (ESI) (M+H)+: m/z (%) 248 (61)。
MS (ESI) (M+H)+: m/z (%) 218.2 (87)。
1HNMR (300 MHz, d6-DMSO) δ 7.41 (d, J = 8.1 Hz, 2H), 7.32 (d, J = 8.1Hz, 2H), 4.10 (s, 1H),3.64 (br s, 2H), 2.24 (br s, 3H);MS (ESI) (M+H)+: m/z (%) 146.1 (10)。
1HNMR (300 MHz, CDCl3) δ 7.86 (d, J = 8.7 Hz, 2H), 7.62 (dd, J = 2.7, 9.6 Hz, 1H), 7.44-7.41 (m, 3H), 7.00 (s, 1H), 4.05 (s, 3H), 3.82 (s, 2H),3.48 (s, 1H),2.49 (s, 3H); MS (ESI) (M+H)+: m/z (%) 314.1 (30)。
1HNMR (300 MHz, d6-DMSO) δ 7.97-7.94 (m, 3H), 7.88 (br s, 1H), 7.64 (dd, J = 2.7, 8.4 Hz, 1H), 7.50-7.42 (m, 4H), 3.70(s, 2H),2.28 (s, 3H); MS (EI) (M): m/z (%) 298 (100)。
N-メチル-1-(4-エチニルフェニル)メチルアミン(化合物8b)の製造:
1HNMR (300 MHz, d6-DMSO) δ 7.41 (d, J = 8.1 Hz, 2H), 7.32 (d, J = 8.1Hz, 2H), 4.10 (s, 1H),3.64 (br s, 2H), 2.24 (br s, 3H);MS (ESI) (M+H)+: m/z (%) 146.1 (10)。
2-{4-[(ジメチルアミノ)メチル]フェニル}-5-フルオロ-3-クロロベンゾフラン-7-カルボン酸メチル(化合物6a)の製造:
1HNMR (300 MHz, CDCl3) δ 8.12 (d, J = 8.1 Hz, 2H), 7.70 (dd, J = 2.7, 9.3 Hz, 1H), 7.47-7.44 (m, 3H), 4.04 (s, 3H), 3.50 (s, 2H),2.27 (s, 6H); MS (ESI) (M+H)+: m/z (%) 362.1 (100), 364.1 (33)。
1HNMR (300 MHz, CDCl3) δ 7.99 (d, J = 8.7 Hz, 2H), 7.84 (dd, J =2.7, 9.6 Hz, 1H), 7.47 (d, J = 8.7 Hz, 2H), 743 (dd, J = 2.7, 7.2 Hz, 1H) 6.28 (s, 1H), 3.50 (s, 2H),2.28 (s, 6H); MS (ESI) (M+H)+: m/z (%) 347.1 (100), 349.1 (33)。
5-[(トリメチルシリル)エチニル]ピリジン-2-ホルムアルデヒド(化合物13a)の製造:
1HNMR (300 MHz, CDCl3) δ 10.05 (s, 1H), 8.80 (s, 1H), 7.89 (s, 2H), 0.28 (s, 9H); MS (ESI) (M+H)+: m/z (%) 204.1 (64)。
1HNMR (300 MHz, CDCl3) δ 10.07 (s, 1H), 8.84 (s, 1H), 7.93 (s, 2H), 3.42 (s, 1H); MS (ESI) (M+H)+: m/z (%) 132.1 (64)。
1HNMR (300 MHz, CDCl3) δ 8.65 (d, J=1.5 Hz, 1H), 7.73 (dd, J=2.1, 8.1 Hz, 1H), 7.27 (d, J=8.1 Hz, 1H), 3.87 (s, 2H), 3.18 (s, 1H) , 2.46 (s, 3H); MS (ESI) (M+H)+: m/z (%) 147.1 (100)。
1HNMR (300 MHz, CDCl3) δ 9.07 (d, J = 1.8 Hz, 1H), 8.15 (dd, J = 2.1, 8.4 Hz, 1H), 7.66 (dd, J = 2.1, 8.4 Hz, 1H), 7.47-7.42 (m, 2H), 7.10 (s, 1H), 4.05 (s, 3H), 3.94 (s, 2H), 2.51 (s, 3H); MS (ESI) (M+H)+: m/z (%) 315.1 (100)。
1HNMR (300 MHz, CD3OD) δ 9.09 (s, 1H), 8.32 (dd, J = 2.1, 8.1 Hz, 1H), 7.58-7.51 (m, 3H), 7.44 (s, 1H), 3.96 (s, 2H), 2.49 (s, 3H); MS (ESI) (M+H)+: m/z (%) 300.1 (100)。
6-[(トリメチルシリル)エチニル]ピリジン-3-ホルムアルデヒド(化合物13b)の製造:
1HNMR (300 MHz, CDCl3) δ 10.09 (s, 1H), 9.01 (s, 1H), 8.12 (dd, J = 1.2, 8.1 Hz, 1H), 7.59(d, J = 1.2 Hz, 1H), 0.28 (s, 9H); MS (ESI) (M+H)+: m/z (%) 204.1 (22)。
1HNMR (300 MHz, CDCl3) δ 10.12 (s, 1H), 9.04 (d, J = 0.9 Hz, 1H), 8.15 (dd, J = 2.1, 8.1 Hz, 1H), 7.63 (d, J = 8.1 Hz, 1H), 3.39 (s,1H); MS (ESI) (M+H)+: m/z (%) 132.1 (59)。
1HNMR (300 MHz, CDCl3) δ 8.52 (d, J = 2.1 Hz, 1H), 7.65 (dd, J = 2.1, 8.4 Hz, 1H), 7.45 (d, J = 8.4 Hz, 1H), 3.77 (s, 2H), 3.12 (s,1H) , 2.45 (s,3H); MS (ESI) (M+H)+: m/z (%) 147.1 (100)。
1HNMR (300 MHz, CDCl3) δ 8.62 (s, 1H), 7.99 (d, J = 7.1 Hz, 1H), 7.81 (dd, J = 1.8, 7.1 Hz, 1H), 7.67 (dd, J = 2.7, 9.6 Hz, 1H), 7.49(dd, J = 2.4, 8.7 Hz, 1H), 7.44 (s, 1H), 4.05 (s,3H), 3.84 (s, 2H), 2.49 (s, 3H); MS (ESI) (M+H)+: m/z (%) 315.1 (100)。
1HNMR (300 MHz, CD3OD) δ 8.63 (s, 1H), 8.06 (d, J = 8.4 Hz, 1H), 7.94 (dd, J = 1.8, 8.1 Hz, 1H), 7.67-7.58 (m, 3H), 3.82 (s, 2H), 2.43 (s, 3H); MS (ESI) (M+H)+: m/z (%) 300.1 (100)。
4-[(トリメチルシリル)エチニル]-2-フルオロベンズアルデヒド(化合物13c)の製造:
1HNMR (300 MHz, CDCl3) δ 10.32 (s, 1H), 7.79 (t, J = 7.8 Hz, 1H), 7.32 (d, J = 7.8 Hz, 1H), 7.24 (m, 1H), 0.26 (s, 9H); MS (ESI) (M+H)+: m/z (%) 221.0 (10)。
1HNMR (300 MHz, CDCl3) δ 10.34 (s, 1H), 7.83 (t, J = 7.8 Hz, 1H), 7.37 (d, J = 7.8 Hz, 1H), 7.28 (d, J = 7.8 Hz, 1H), 3.34 (s, 1H)。
MS (ESI) (M+H)+: m/z (%) 164.1 (38)。
MS (ESI) (M+H)+: m/z (%) 332.1 (100)。
1HNMR (300 MHz, CD3OD) δ 7.83-7.76 (m, 2H), 7.64 (t, J = 7.8 Hz, 1H), 7.57-7.50 (m, 2H), 7.41 (s, 1H), 4.22 (s, 2H), 2.71 (s, 3H); MS (ESI) (M+H)+: m/z (%) 317.2 (100)。
1-(4-エチニルベンジル)ピロリジン(化合物8f)の製造:
1HNMR (300 MHz, CDCl3) δ 7.44 (d, J = 7.5 Hz, 2H), 7.28 (d, J = 8.4 Hz, 2H), 3.62 (s, 2H), 3.04 (s, 1H),2.51 (m, 4H), 1.79(m, 4H); MS (ESI) (M+H)+: m/z (%) 186.2 (100)。
1HNMR (300 MHz, CDCl3) δ 7.85 (d, J = 6.3 Hz, 2H), 7.62 (dd, J = 2.1, 7.1Hz, 1H), 7.45-7.41 (m, 3H), 7.00 (s, 1H), 4.05 (s,3H), 3.67 (s, 2H), 2.54 (m, 4H), 1.80 (m, 4H); MS (ESI) (M+H)+: m/z (%) 354.2 (100)。
1HNMR (300 MHz, CD3OD) δ 7.92 (d, J = 8.4 Hz, 2H), 7.47-7.56 (m, 4H), 7.30 (s, 1H), 3.73 (s, 2H), 2.62 (m, 4H) , 1.86-1.82 (m, 4H); MS (ESI) (M+H)+: m/z (%) 339.2 (100)。
1-(4-エチニルベンジル)-4-メチルピペラジン(化合物8g)の製造:
1HNMR (300 MHz, CDCl3) δ 7.42 (d, J = 8.1 Hz, 2H), 7.26 (d, J = 8.1 Hz, 2H), 3.49 (s, 2H), 3.05(s, 1H),2.44(br s, 8H), 2.28(s, 3H); MS (ESI) (M+H)+: m/z (%) 215.2 (100)。
1HNMR (300 MHz, CDCl3) δ 7.84 (d, J = 8.4 Hz, 2H), 7.62 (dd, J = 2.4, 9.6 Hz, 1H), 7.44-7.40 (m, 3H), 7.00 (s, 1H), 4.05(s,3H), 3.56(s, 2H), 2.50(br s, 8H), 2.30(s, 3H); MS (ESI) (M+H)+: m/z (%) 383.2 (100)。
1HNMR (300 MHz, CD3OD) δ 7.90 (d, J = 8.1 Hz, 2H), 7.56-7.45 (m, 4H), 7.29 (s, 1H), 3.58 (s, 2H), 2.52 (br s, 8H) , 2.28(s, 3H); MS (ESI) (M+H)+: m/z (%) 368.2 (100)。
1-(4-エチニルベンジル)ピぺリジン(化合物8h)の製造:
1HNMR (300 MHz, CDCl3) δ 7.42 (d, J = 8.4 Hz, 2H), 7.27 (d, J = 8.1 Hz, 2H), 3.46 (s, 2H), 3.04 (s, 1H),2.36 (m, 4H), 1.60-1.53(m, 4H), 1.46-1.40(m, 2H); MS (ESI) (M+H)+: m/z (%) 200.2 (100)。
1HNMR (300 MHz, CDCl3) δ 7.85 (d, J=8.1 Hz, 2H), 7.62 (dd, J=2.7, 9.0 Hz, 1H), 7.45-7.41 (m, 3H), 7.00 (s, 1H), 4.05 (s,3H), 3.53(s, 2H), 2.41 (m, 4H), 1.63-1.57 (m, 4H), 1.47-1.43 (m, 2H); MS (ESI) (M+H)+: m/z (%) 368.2 (100)。
1HNMR (300 MHz, CD3OD) δ 7.75-7.66 (m, 3H), 7.44-7.35 (m, 3H), 7.03 (s, 1H), 3.52 (s, 2H), 2.41 (m, 4H), 1.63-1.57 (m, 4H), 1.47-1.43 (m, 2H); MS (ESI) (M+H)+: m/z (%) 353.2 (100)。
1-(4-エチニルベンジル)-4-メチルホモピペラジン(化合物8i)の製造:
1HNMR (300 MHz, CDCl3) δ 7.42 (d, J = 8.1 Hz, 2H), 7.30 (d, J = 8.1 Hz, 2H), 3.62 (s, 2H), 3.04 (s, 1H), 2.71-2.57 (m, 8H), 2.35 (s, 3H), 1.84-1.78 (m, 2H); MS (ESI) (M+H)+: m/z (%) 229.2 (100)。
1HNMR (300 MHz, CDCl3) δ 7.84 (d, J = 8.1 Hz, 2H), 7.62 (dd, J = 2.4, 9.3 Hz, 1H), 7.54-7.40 (m, 3H), 6.99 (s, 1H), 4.04 (s,3H), 3.68(s, 2H), 2.71-2.57 (m, 8H), 2.41 (s, 3H), 1.84-1.78 (m, 2H); MS (ESI) (M+H)+: m/z (%) 397.2 (100)。
1HNMR (300 MHz, CDCl3) δ 7.78-7.72 (m, 3H), 7.47-7.36 (m, 4H), 7.02 (s, 1H), 6.66 (br s, 1H) , 3.68 (s, 2H), 2.76-2.64 (m, 8H), 2.38 (s, 3H), 1.88-1.80 (m, 2H); MS (ESI) (M+H)+: m/z (%) 382.2 (100)。
1-(4-エチニルベンジル)モルホリン(化合物8j)の製造:
1HNMR (300 MHz, CDCl3) δ 7.43 (d, J = 8.4 Hz, 2H), 7.28 (d, J = 8.4 Hz, 2H), 3.70 (t, J = 5.1 Hz, 4H), 3.48 (s, 2H), 3.05 (s, 1H), 2.43 (t, J=4.8 Hz, 4H); MS (ESI) (M+H)+: m/z (%) 202.1 (100)。
MS (ESI) (M+H)+: m/z (%) 370.2 (100)。
1HNMR (300 MHz, CDCl3) δ 7.80-7.68 (m, 3H), 7.47-7.33 (m, 4H), 7.05 (s, 1H), 6.31 (s, 1H), 3.73 (t, J = 4.8 Hz, 4H), 3.56 (s, 2H), 2.47 (t, J = 4.8Hz, 4H); MS (ESI) (M+H)+: m/z (%) 355.2 (100)。
1-(4-エチニルベンジル)チオモルホリン(化合物8k)の製造:
1HNMR (300 MHz, CDCl3) δ 7.43 (d, J = 8.1 Hz, 2H), 7.26 (d, J = 8.1 Hz, 2H), 3.50 (s, 2H), 3.05(s, 1H), 2.67(br s, 8H); MS (ESI) (M+H)+: m/z (%) 218.1 (100)。
MS (ESI) (M+H)+: m/z (%) 386.1 (100)。
1HNMR (300 MHz, CDCl3) δ 7.81-7.68 (m, 3H), 7.48-7.39 (m, 4H), 7.05 (s, 1H), 6.28 (br s, 1H), 3.57 (s, 2H), 2.74-2.68 (m, 8H); MS (ESI) (M+H)+: m/z (%) 371.1 (100)。
4-[(4-エチニルベンジル)アミノ]ピペリジン-1-カルボン酸-t-ブチル(化合物8l)の製造:
1HNMR (300 MHz, CDCl3) δ 7.44 (d, J = 8.4 Hz, 2H), 7.26 (d, J = 9.3 Hz, 2H), 4.00 (m, 2H), 3.82 (s, 2H), 3.05 (s, 1H), 2.79 (t, J = 10.8 Hz, 2H), 2.64 (m, 1H), 1.83 (m, 2H), 1.45 (s, 9H), 1.28 (m, 2H); MS (ESI) (M+H)+: m/z (%) 315.2 (54)。
MS (ESI) (M+H)+: m/z (%) 483.3(95)。
1HNMR (300 MHz, CDCl3) δ 7.79-7.74 (m, 3H), 7.46-7.38 (m, 4H), 7.04 (s, 1H), 6.31 (br s, 1H), 4.04 (br s, 2H), 3.89 (s, 2H), 2.81 (t, J = 8.7Hz, 2H), 2.70 (m, 1H), 1.88 (m, 2H), 1.45 (s, 9H), 1.32 (m, 2H); MS (ESI) (M-99)+: m/z (%) 368.2 (100)。
1HNMR (300 MHz, CDCl3) δ 7.79-7.68 (m, 3H), 7.46-7.37 (m, 4H), 7.04 (s, 1H), 6.52 (br s, 1H), 3.88 (s, 2H), 3.11 (m, 2H), 2.61 (m, 3H), 1.92 (m, 2H), 1.32 (br s, 2H); MS (ESI) (M+H)+: m/z (%) 368.2 (100)。
(R)-N-(4-エチニルベンジル)-3-アミノテトラヒドロフラン(化合物8m)の製造:
1HNMR (300 MHz, CDCl3) δ 7.44 (d, J = 6.0 Hz, 2H), 7.28 (d, J = 6.0 Hz, 2H), 3.92 (m, 1H),3.81-3.74 (s, 4H), 3.61 (m, 1H), 3.41 (m, 1H),3.06 (s, 1H), 2.10 (m, 1H), 1.74 (m, 1H); MS (ESI) (M+H)+: m/z (%) 202.1 (95)。
MS (ESI) (M+H)+:m/z (%) 370.2 (95)。
1HNMR (300 MHz, CDCl3) δ 7.80-7.74 (m, 3H), 7.45 (d, J = 8.4 Hz, 2H), 7.40 (m, 2H), 7.04 (s, 1H), 6.37 (s, 1H), 4.00-3.92 (m, 1H), 3.85-3.75 (m, 4H), 3.69-3.64 (m, 1H), 3.50-3.43 (m, 1H), 2.20-2.08 (m, 1H), 1.85-1.78 (m,1H); MS (ESI) (M+H)+: m/z (%) 355.2 (100)。
N-(4-エチニルベンジル)シクロプロピルアミン(化合物8n)の製造:
1HNMR (300 MHz, CDCl3) δ 7.44 (d, J = 8.1 Hz, 2H), 7.26 (d, J = 8.1 Hz, 2H), 3.83 (s, 2H),3.05 (s, 1H), 2.16-2.09 (m, 1H), 0.46-0.33 (m, 4H) MS (ESI) (M+H)+: m/z (%) 172.2 (30)。
MS (ESI) (M+H)+: m/z (%) 340.2 (60)。
1HNMR (300 MHz, CDCl3/CD3OD) δ 7.75-7.68 (m, 3H), 7.41-7.35 (m, 3H), 7.02 (s, 1H), 3.84 (s, 2H), 2.16-2.09 (m, 1H), 0.48-0.35 (m, 4H); MS (ESI) (M+H)+: m/z (%) 325.2 (52)。
N-(4-エチニルベンジル)イソプロピルアミン(化合物8o)の製造:
1HNMR (300 MHz, CDCl3) δ 7.43 (d, J = 8.4 Hz, 2H), 7.26 (d, J = 8.4 Hz, 2H), 3.77 (s, 2H),3.04 (s, 1H) , 2.89-2.78 (m, 1H), 1.08 (d, J = 6.3 Hz, 6H); MS (ESI) (M+H)+: m/z (%) 174.2(73)。
MS (ESI) (M+H)+: m/z (%) 342.2 (100)。
1HNMR (300 MHz, CDCl3) δ 7.74-7.72 (m, 3H), 7.43-7.35 (m, 4H), 7.02 (s, 1H), 6.36 (s, 1H), 3.82 (s, 2H), 2.85 (m, 1H), 1.09(d, J=6.3Hz, 6H); MS (ESI) (M+H)+: m/z (%) 327.(100)。
4-[(トリメチルシリル)エチニル]-3-フルオロベンズアルデヒド(化合物13d)の製造:
1HNMR (300 MHz, CDCl3) δ 9.96 (d, J = 1.2, 1H), 7.61-7.54 (m, 3H), 0.28 (s, 9H); MS (ESI) (M+H)+: m/z (%) 221.1 (100)。
1HNMR (300 MHz, CDCl3) δ 9.97 (s, 1H), 7.68-7.57 (m, 3H), 3.57 (s, 1H); MS (ESI) (M+H)+: m/z (%) 149.1 (10)。
1HNMR (300 MHz, CDCl3) δ 7.42 (d, J = 7.8 Hz, 1H), 7.09-7.04(m, 2H), 3.74 (s, 2H), 3.27 (s,1H), 2.43 (s,3H); MS (ESI) (M+H)+: m/z (%) 164.1 (26)。
1HNMR (300 MHz, CDCl3) δ 8.05 (t, J = 7.8 Hz, 1H), 7.64 (dd, J = 2.7, 9.3 Hz, 1H), 7.44 (dd, J = 2.7, 8.1 Hz, 1H), 7.24-7.12 (m, 3H), 4.04 (s,3H), 3.80 (s, 2H), 2.47 (s, 3H); MS (ESI) (M+H)+: m/z (%) 332.1 (10)。
1HNMR (300 MHz, CD3OD) δ 8.03 (t, J = 7.9 Hz, 1H), 7.55 (m, 2H), 7.34-7.24 (m, 3H), 3.77 (s, 2H), 2.40 (s, 3H; MS (ESI) (M+H)+: m/z (%) 317.2 (50)。
2-{4-[(ジメチルアミノ)メチル]フェニル}-5-フルオロベンゾフラン-7-カルボキサミド塩酸塩の製造:
1HNMR (300 MHz, d6-DMSO) δ 10.96 (br s, 1H), 8.09 (d, J = 8.1 Hz, 2H), 7.95 (s, 1H), 7.91 (s, 1H), 7.76-7.68 (m, 3H), 7.61 (s, 1H), 7.50 (dd, J = 2.4, 9.9Hz, 1H), 4.33 (d, J = 5.4Hz, 2H), 2.70 (d, J = 4.8Hz, 6H)。
2-{4-[(メチルアミノ)メチル]フェニル}-5-フルオロベンゾフラン-7-カルボキサミド塩酸塩の製造:
1HNMR (300 MHz, d6-DMSO) δ 9.42 (br s, 2H), 8.07 (d, J = 8.1 Hz, 2H), 7.94 (s, 1H), 7.91 (s, 1H), 7.72-7.67 (m, 3H), 7.59 (s, 1H), 7.50 (dd, J =2.7, 9.9 Hz, 1H), 4.17 (t, J = 5.4 Hz, 2H), 2.70 (d, J = 5.1 Hz, 3H)。
分子レベルのPARP1酵素活性阻害実験:
実験方法:酵素結合免疫吸着法(Enzyme-Linked Immunosorbent Assay, ELISA)(Decker P.によって発表された文献に記載の酵素結合免疫吸着法を参照する。参照文献:Decker P, Miranda EA, de Murcia G, Muller S. An improved nonisotopic test to screen a large series of new inhibitor molecules of Poly(ADP-ribose) Polymerase activity for therapeutic applications. Clinical Cancer Research, 5:1169-1172, 1999.)。
1.ヒストンは、周知のPARP1の重要な基質である。ヒストンを無カリウムイオンのPBS(10 mMリン酸ナトリウム緩衝液、150 mM NaCl、pH 7.2-7.4)で96ウェルプレートを被覆し、37℃で一晩シェーカーに置いた後、ウェルにおける液体を捨てた。120 μL/ウェルのT-PBS(0.1%Tween-20含有PBS)でプレートを5回洗浄した。37℃のオーブンで乾燥した。
4.PBS-Tでプレートを3回洗浄し、ペルオキシダーゼで標識された第二抗体(抗マウス抗体)(1:2000、5 μg/mL BSA含有PBS-Tで希釈したもの)を100μL/ウェル入れ、37℃のシェーカーで30分間反応させた。
算式:阻害率(%)=(OD対照ウェル-OD投与ウェル)/OD対照ウェル×100%で薬物のPARP酵素活性に対する阻害程度を計算し、且つこれに基づいてLogit法で阻害率50%に達した時の薬物濃度、すなわちIC50値を算出した。実験を3回繰り返し、平均値と標準偏差を算出した。
体外細胞の増殖阻害実験:
細胞株:チャイニーズハムスター肺線維芽細胞株VC8(BRCA2-/-)と野生型細胞株V79(オランダライデン大学の教授から受贈)。
実験方法:MTT比色法(Mosman T.によって発表されたMTT比色法を参照する。参照文献:Mosmann T. Rapid colorimetric assay for cellular growth and survival application to proliferation and cytotoxicity assasys. Journal of Immunological Methods 65(1-2):55-63, 1983.)。MTTの正式な名称は3-(4,5-ジメチル-チアゾール-2-イル)-2,5-ジフェニルテトラゾリウムブロミド(3-(4,5-dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium bromide)である。)。
分子レベルのPARPファミリー酵素活性阻害実験:
実験方法:酵素結合免疫吸着法(Enzyme-Linked Immunosorbent Assay, ELISA)。その原理は、基質であるヒストンを吸着性の96ウェルプレートに被覆させ、PARP1組換え酵素、基質NAD+、活性化したDNAを入れてPARP1を酵素反応させ、ヒストンに産物のPAR(ポリ(アデノシン二リン酸リボース))を生成させた後、抗PAR(anti-PAR)抗体を入れ、96ウェルプレートに被覆されたヒストンにおける産物のPARの強度を検出することで、PARP酵素の活性を反映することができる。
1.酵素反応基質であるヒストンを無カリウムイオンのPBS(10 mMリン酸ナトリウム緩衝液、150 mM NaCl、pH 7.2-7.4)で96ウェルプレートを被覆し、37℃で一晩シェーカーに置いた後、ウェルにおける液体を捨てた。120 μL/ウェルのT-PBS(0.1%Tween-20含有PBS)でプレートを5回洗浄し、37℃のオーブンで乾燥した。
4.100μLの呈色液を入れ、マイクロプレートリーダーBioTek SynergyTM 2で蛍光(Luminescence)数値を読み取った。算式:阻害率(%)=(L対照ウェル-L投与ウェル)/L対照ウェル×100%で化合物の酵素に対する阻害程度を計算し、且つこれに基づいてLogit法で阻害率50%に達した時の化合物濃度、すなわちIC50値を算出した。実験を3回繰り返し、平均値と標準偏差を算出した。
1.投与プラン
体重200〜220gのオスの健康SDラット(にShanghai Sippr-BK Lab. Animal Co. Ltdよって提供されたもの。実験動物生産許可証番号:SCXK(滬))を無作為に組み分けし、それぞれ胃灌流した。化合物は、生理食塩水で調製された。
採血の時点およびサンプルの処理:胃灌流投与、投与後0.25、0.5、1.0、2.0、3.0、5.0、7.0、9.0、24hを経た時点でラットの眼球後静脈叢から静脈血0.3mLを取り、ヘパリンで処理した試験管に置き、11000rpmで5 min遠心し、血漿を分離し、-20℃の冷蔵庫で冷凍した。
化合物5bを10mg/kg胃灌流投与後、ラット体内の血漿濃度がピークに達した時間Tmaxは3.5±2.4hで、ピークに達した時の濃度Cmaxは92.5±33.2ng/mLで、血漿濃度-時間曲線下面積AUC0-tは452±103 ng・h/mLで、排泄半減期t1/2は1.75±0.94 hで、平均滞留時間MRTは3.94±1.13時間であった。ラットの化合物5bを10mg/kg胃灌流投与後の絶対生物的利用能が58.9%であった。
初歩の薬物動態学実験では、化合物5bの体内の除去速度が適切で、生物的利用能が高く、ラットの化合物5bを10mg/kg胃灌流投与後の絶対生物的利用能が58.9%で、体内の吸収、分布、代謝の状況が優れたことが示されたが、II期臨床試験化合物AZD2281のラットの経口投与の生物的利用能が11.1%しかない。
Claims (8)
- 一般式I
R1とR2は、それぞれ独立に水素、C1-C4の直鎖もしくは分枝鎖のアルキル基、C3-C4のシクロアルキル基または酸素もしくは窒素を含有する飽和の5員もしくは6員の複素環基で、
あるいは、R1およびR2は、Nと一緒になって少なくとも一つのヘテロ原子を含有する無置換もしくは置換の飽和の5員もしくは6員の複素環基を形成するか、またはホモピペラジル基を形成し、ここで、前記ヘテロ原子はO、NおよびSで、前記置換基はNにあるメチル基で、
R3は、水素原子または塩素原子で、
R4は、水素原子またはフッ素原子で、
Xは、CH、CFまたはNで、
Yは、CH、CFまたはNである、
で表される2-アリールベンゾフラン-7-カルボキサミド化合物またはその薬理学的または生理学的に許容される塩。 - R1が、水素、メチル基、エチル基、イソプロピル基、シクロプロピル基、ピペリジン-4-イル基または(R)テトラヒドロフラン-3-イル基で、
R2が、水素、メチル基、エチル基、イソプロピル基、シクロプロピル基、ピペリジン-4-イル基または(R)テトラヒドロフラン-3-イル基で、
あるいは、R1およびR2が、Nと一緒になって無置換もしくは置換の、モルホリル基、ピペラジル基、ホモピペラジル基、チオモルホリル基、ピペリジル基またはピロリジル基を形成し、ここで、前記置換基はNにあるメチル基で、
R3が、水素原子で、
R4が、フッ素原子で、
Xが、CH、CFまたはNで、
Yが、CH、CFまたはNである、請求項1に記載の化合物またはその薬理学的または生理学的に許容される塩。 - R1が、水素またはメチル基で、
R2が、メチル基、イソプロピル基、シクロプロピル基、ピペリジン-4-イル基または(R)テトラヒドロフラン-3-イル基で、
あるいは、R1およびR2が、Nと一緒になって無置換もしくは置換の、モルホリル基、ピペラジル基、ホモピペラジル基、チオモルホリル基、ピペリジル基またはピロリジル基を形成し、ここで、前記置換基はNにあるメチル基で、
R3が、水素原子で、
R4が、フッ素原子で、
Xが、CH、CFまたはNで、
Yが、CH、CFまたはNである、
請求項2に記載の化合物またはその薬理学的または生理学的に許容される塩。 - 化合物が、以下の化合物である、請求項3に記載の化合物またはその薬理学的または生理学的に許容される塩。
- 薬理学的または生理学的に許容される塩が、塩酸塩である、請求項1〜4のいずれか一項に記載の化合物またはその薬理学的または生理学的に許容される塩。
- 請求項1〜4のいずれか一項に記載の化合物の製造方法であって、
合成経路が、スキーム1
a)5-位置換のサリチル酸1をエステル化反応させて化合物2を生成する工程と、
b)化合物2をヨウ素化反応させて化合物3を生成する工程と、
c)化合物3と置換芳香族アルキン化合物8を薗頭反応させ、閉環して化合物4を生成する工程と、
d)化合物4をハロゲン化反応させて化合物6を生成する工程と、
e)化合物4または化合物6をアンモノリシス反応させてそれぞれ化合物5または化合物Iを生成する工程と、
を含み、
前記置換芳香族アルキン化合物8の構造式は、以下のとおりであり、
- PARP関連疾患を治療する薬物の製造における請求項1〜5のいずれか一項に記載の化合物またはその薬理学的または生理学的に許容される塩の使用。
- PARP関連疾患を治療する薬物が、抗腫瘍薬、抗炎症薬である、請求項7に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210028895.0A CN103242273B (zh) | 2012-02-09 | 2012-02-09 | 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途 |
CN201210028895.0 | 2012-02-09 | ||
PCT/CN2013/070410 WO2013117120A1 (zh) | 2012-02-09 | 2013-01-14 | 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015511942A JP2015511942A (ja) | 2015-04-23 |
JP5926821B2 true JP5926821B2 (ja) | 2016-05-25 |
Family
ID=48922178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014555927A Active JP5926821B2 (ja) | 2012-02-09 | 2013-01-14 | 2−アリールベンゾフラン−7−カルボキサミド系化合物、その製造方法および用途 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9533965B2 (ja) |
EP (1) | EP2813495B1 (ja) |
JP (1) | JP5926821B2 (ja) |
CN (1) | CN103242273B (ja) |
BR (1) | BR112014019402B1 (ja) |
CA (1) | CA2863988C (ja) |
RU (1) | RU2583900C2 (ja) |
WO (1) | WO2013117120A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102627620B (zh) * | 2012-04-10 | 2015-12-16 | 江苏先声药物研究有限公司 | 一类苯并呋喃衍生物及其医药应用 |
WO2014102817A1 (en) | 2012-12-31 | 2014-07-03 | Cadila Healthcare Limited | Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1 |
CN105272936B (zh) * | 2014-05-27 | 2019-05-17 | 中国科学院上海药物研究所 | 一类氮芳基苯并噻唑类parp抑制剂及其制备方法和用途 |
CN109134409B (zh) * | 2017-06-14 | 2023-09-29 | 中国科学院上海药物研究所 | 盐酸美呋哌瑞多晶型物及其制备方法与应用 |
CN111320596B (zh) * | 2018-12-14 | 2024-07-05 | 甫康(上海)健康科技有限责任公司 | 盐酸美呋哌瑞多晶型物及其制备方法 |
CN113116881A (zh) * | 2019-12-31 | 2021-07-16 | 甫康(上海)健康科技有限责任公司 | 一种用于治疗肿瘤的药物组合及其应用 |
EP4112049A1 (en) | 2020-02-24 | 2023-01-04 | Fukang (Shanghai) Health Technology Co., Ltd. | Anti-coronavirus application of poly adp ribose polymerase inhibitor |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL87451A0 (en) | 1987-09-04 | 1989-01-31 | Tanabe Seiyaku Co | Benzofuran derivatives,their preparation and pharmaceutical compositions containing them |
AU9297998A (en) * | 1998-05-15 | 1999-12-06 | Guilford Pharmaceuticals Inc. | Carboxamide compounds, compositions, and methods for inhibiting parp activity |
ES2449713T3 (es) * | 1998-11-03 | 2014-03-20 | Abbvie Deutschland Gmbh & Co Kg | 2-fenilbencimidazoles sustituidos y su empleo como inhibidores de PARP |
SI1131301T1 (sl) * | 1998-11-17 | 2006-02-28 | Abbott Gmbh & Co Kg | 2-fenilbenzimidazoli in 2-fenilindoli, njihova priprava in uporaba |
DE10022925A1 (de) * | 2000-05-11 | 2001-11-15 | Basf Ag | Substituierte Indole als PARP-Inhibitoren |
US7435837B2 (en) * | 2003-10-24 | 2008-10-14 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
DE10351315A1 (de) | 2003-10-31 | 2005-06-16 | Aventis Pharma Deutschland Gmbh | 2-Phenyl-benzofuran-Derivate, Verfahren zur ihrer Herstellung und ihre Verwendung |
SI1794163T1 (sl) * | 2004-09-22 | 2010-04-30 | Pfizer | Postopek priprave inhibitorjev poli(ADP-riboza) polimeraz |
JP5162465B2 (ja) * | 2005-11-15 | 2013-03-13 | アボット・ラボラトリーズ | 置換1h−ベンズイミダゾール−4−カルボキサミド類は強力なparp阻害薬である |
WO2007131016A2 (en) * | 2006-05-02 | 2007-11-15 | Abbott Laboratories | Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors |
KR101491998B1 (ko) * | 2006-12-28 | 2015-02-10 | 애브비 인코포레이티드 | 폴리(adp-리보스)폴리머라제 억제제 |
EP2129670A2 (en) | 2007-02-16 | 2009-12-09 | Glaxo Group Limited | Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor |
WO2009009417A2 (en) | 2007-07-06 | 2009-01-15 | Wyeth | Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion |
CN101998959B (zh) * | 2008-02-06 | 2013-08-28 | 生物马林药物股份有限公司 | 聚(adp-核糖)聚合酶(parp)的苯并噁唑甲酰胺抑制剂 |
GB0806656D0 (en) | 2008-04-11 | 2008-05-14 | Karobio Ab | Novel estrogen receptor ligands |
EP2355825A2 (en) * | 2008-11-10 | 2011-08-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
US8476309B2 (en) | 2009-08-20 | 2013-07-02 | The University Of Tennessee Research Foundation | Benzofuran cannabinoid compounds and related methods of use |
GB0919380D0 (en) * | 2009-11-04 | 2009-12-23 | Almac Discovery Ltd | Pharmaceutical compouds |
CN102627620B (zh) | 2012-04-10 | 2015-12-16 | 江苏先声药物研究有限公司 | 一类苯并呋喃衍生物及其医药应用 |
-
2012
- 2012-02-09 CN CN201210028895.0A patent/CN103242273B/zh active Active
-
2013
- 2013-01-14 US US14/375,742 patent/US9533965B2/en active Active
- 2013-01-14 RU RU2014132159/04A patent/RU2583900C2/ru active
- 2013-01-14 WO PCT/CN2013/070410 patent/WO2013117120A1/zh active Application Filing
- 2013-01-14 CA CA2863988A patent/CA2863988C/en active Active
- 2013-01-14 EP EP13746724.7A patent/EP2813495B1/en active Active
- 2013-01-14 JP JP2014555927A patent/JP5926821B2/ja active Active
- 2013-01-14 BR BR112014019402-5A patent/BR112014019402B1/pt active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
CA2863988A1 (en) | 2013-08-15 |
US20150018542A1 (en) | 2015-01-15 |
BR112014019402A8 (pt) | 2017-07-11 |
EP2813495A4 (en) | 2015-06-17 |
RU2014132159A (ru) | 2016-03-27 |
RU2583900C2 (ru) | 2016-05-10 |
BR112014019402A2 (ja) | 2017-06-20 |
BR112014019402B1 (pt) | 2020-12-15 |
WO2013117120A1 (zh) | 2013-08-15 |
CA2863988C (en) | 2016-03-22 |
US9533965B2 (en) | 2017-01-03 |
CN103242273B (zh) | 2015-06-03 |
CN103242273A (zh) | 2013-08-14 |
EP2813495B1 (en) | 2016-09-28 |
JP2015511942A (ja) | 2015-04-23 |
EP2813495A1 (en) | 2014-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5926821B2 (ja) | 2−アリールベンゾフラン−7−カルボキサミド系化合物、その製造方法および用途 | |
CN100543022C (zh) | 2-呋喃甲酸酰肼化合物及含该化合物的药物组合物 | |
KR100618074B1 (ko) | 벤즈아미드 유도체 및 이것의 사이토킨 억제제로서 용도 | |
ES2266907T3 (es) | Derivados sustituidos del acido 3-carbonil-indol-1-il-acetico como inhibidor del activador del plasminogeno-1 (pal-1). | |
WO2008059867A1 (fr) | Nouveau dérivé de 1,2-dihydroquinoline comprenant en tant que substituants un groupe alkyle inférieur-carbonyloxy (à substitution phényle ou substitution hétérocyclique) et un groupe phényle lié par un ester | |
KR20010099609A (ko) | 사이토킨의 생성 억제제로서 유용한 아미드 유도체 | |
WO2002006264A1 (fr) | Inhibiteurs de plaques riches en lipide | |
TW200417546A (en) | New compounds | |
WO2013075596A1 (zh) | 作为dhodh抑制剂的五元二氢杂环酮类衍生物及应用 | |
WO2024040768A1 (zh) | 5-吡啶-1h-吲唑类化合物、药物组合物和应用 | |
CN107163044A (zh) | 一类具有蛋白酶修饰活性的萘乙二酮化合物及其衍生物 | |
Zhang et al. | Design, synthesis and biological activity evaluation of novel methyl substituted benzimidazole derivatives | |
WO2002055484A1 (fr) | Compose biaryle, procede de production de ce compose, et principe actif | |
Suryavanshi et al. | Design, synthesis and docking study of Vortioxetine derivatives as a SARS-CoV-2 main protease inhibitor | |
JPWO2003011812A1 (ja) | ヒト−β−トリプターゼ阻害活性を有する新規アミン誘導体およびそれを含有する医薬 | |
Schuler et al. | Boronic acid-containing aminopyridine-and aminopyrimidinecarboxamide CXCR1/2 antagonists: Optimization of aqueous solubility and oral bioavailability | |
CN109096272B (zh) | 一种具有抗肿瘤活性的吲哚异羟肟酸类化合物及其应用 | |
Zheng et al. | Design and synthesis optimization of novel diimide indoles derivatives for ameliorating acute lung injury through modulation of NF-κB signaling pathway | |
EP1844775B1 (en) | Therapeutic agent for the treatment of herpes progenitalis after development of lesions | |
US20040092515A1 (en) | Diaminoquinazoline esters for use as dihydrofolate reductase inhibitors | |
EP3684354B1 (en) | Xpa inhibitor compounds and their use | |
An et al. | Inhibition of TGF-β1/Smad3 signaling by compound 5aa: A potential treatment for idiopathic pulmonary fibrosis | |
CN104945411A (zh) | 噻吩并[3,2-c]吡啶类化合物、其制备方法及应用 | |
CN110256405A (zh) | 5-烃基-n-取代芳基吡啶酮衍生物及其制备方法和用途 | |
CN108239081A (zh) | 一种抑制rock的化合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151030 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160225 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160412 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160422 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5926821 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |